Unicycive Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Unicycive Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 14, 2025 - UNCY

Core Points - A class action securities lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged securities fraud affecting investors between March 29, 2024, and June 27, 2025 [2][3] - The lawsuit claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its new drug application [3] - Investors who suffered losses during the relevant period have until October 14, 2025, to request to be appointed as lead plaintiff [4] Company Details - Unicycive Therapeutics, Inc. is currently facing legal challenges due to claims of misleading public statements regarding its compliance and regulatory status [3] - The firm Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5]